Levamisole-adulterated cocaine
A report on three clinical cases
Abstract
Consumption of cocaine hydrochloride and cocaine base paste (CBP) in Uruguay has a lifetime prevalence of 6.9% and 0.7% respectively. Complications associated to toxic side effects of cocaine abuse depend on the concentration of the alkaloid, as well as on the presence of adulterants. Levamisole, a veterinary anthelmintic, a well know cocaine adulterant in the US was identified in Uruguay in 2013. This adulterant results in complications such as neutropenia, skin vasculitis, glomerulonephritis and leukoencephalopathy. The study describes the first three clinical cases of complications resulting from cocaine cut with levamisole reported to the Toxicology Center for Information and Counseling. The patients included were chronic cocaine abusers between 35 and 40 years old. Retiform purpura was detected in the three cases with a necrotic center associated to ANCA antibodies, with a tendency to appear in the earlobes, cheeks, and limbs, as it is reported in levamisole associated vasculitis. Neutropenia was reported in one case. The three patients had anemia. Two of the cases presented acute kidney failure. The main treatment was interruption of consumption, what resulted in a complete reversion of complications. All patients required debridement or skin grafts, or both. The above mentioned complications are discussed and analyzed, as well as the risk re-exposure and the suggested treatments involve, as the granulocytes growth factors, broad spectrum antibiotics and corticoids. A high degree of suspicion is required to associate these clinical manifestations to the presence of levamisole as a cocaine adulterant.
References
(1) Uruguay. Junta Nacional de Drogas. VI encuesta nacional en hogares sobre consumo de drogas: datos preliminares. Montevideo: Junta Nacional de Drogas, 2015. Disponible en: http://www.infodrogas.gub.uy/images/stories/pdf/vi_encuesta_hogares_2015.pdf (Consulta: 7 junio 2016).
(2) Pascale A, Hynes M, Cumsille F, Bares C. Consumo de pasta base de cocaína en América del Sur: revisión de los aspectos epidemiológicos y médico-toxicológicos. Washington, DC: OEA, 2014. Disponible en: http://www.cicad.oas.org/oid/pubs/pbc.pdf. (Consulta: 13 setiembre 2016).
(3) Uruguay. Junta nacional de Drogas. Observatorio Uruguayo de Drogas. Sistema de alerta temprana en drogas informa sobre adulteración de cocaína con levamisol. Montevideo: Junta Nacional de Drogas, 2016. Disponible en: http://www.infodrogas.gub.uy/index.php?option=com_content&view=article&id=3488:sistema-de-alerta-temprana-en-drogas-satdrogas-informa-sobre-adulteracion-de-cocaina-con-levamisol&catid=14:noticias&Itemid=59. (Consulta: 12 noviembre 2016).
(4) Williams GT, Johnson SA, Dieppe PA, Huskisson EC. Neutropenia during treatment of rheumatoid arthritis with levamisole. Ann Rheum Dis 1978; 37(4):366-9.
(5) Lee KC, Ladizinski B, Federman DG. Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge. Mayo Clin Proc 2012; 87(6):581-6.
(6) Larocque A, Hoffman RS. Levamisole in cocaine: unexpected news from an old acquaintance. Clin Toxicol (Phila) 2012; 50(4):231-41.
(7) Centers for Disease Control and Prevention. Agranulocytosis associated with cocaine use - four States, March 2008-November 2009. MMWR Morb Mortal Wkly Rep 2009; 58(49):1381-5.
(8) Belfonte CD, Shanmugam VK, Kieffer N, Coker S, Boucree S, Kerr G. Levamisole-induced occlusive necrotising vasculitis in cocaine abusers: an unusual cause of skin necrosis and neutropenia. Int Wound J 2013; 10(5):590-6.
(10) Lawrence LA, Jiron JL, Lin HS, Folbe AJ. Levamisole-adulterated cocaine induced skin necrosis of nose, ears, and extremities: case report. Allergy Rhinol (Providence) 2014; 5(3):132-6.
(11) Jadhav P, Tariq H, Niazi M, Franchin G. Recurrent thrombotic vasculopathy in a former cocaine user. Case Rep Dermatol Med 2015; 2015:763613.
(12) Roca-Argente L, Moll-Guillen JL, Espí-Reig J, Blanes-Julia M, García-Martínez AM, Pujol-Marco C, et al. Membranous glomerulonephritis and cellular crescents induced by levamisole-adulterated cocaine abuse: a case report. Ann Transl Med 2015; 3(18):271.
(14) Baptiste GG, Alexopoulos AS, Masud T, Bonsall JM. Systemic levamisole-induced vasculitis in a cocaine user without cutaneous findings: a consideration in diagnosis. Case Rep Med 2015; 2015:547023.
(15) Pellegrini D, Young P, Grosso V, Massa M, Bruetman JE. Agranulocitosis por levamisol asociado a cocaína. Medicina (B. Aires) 2013; 73(5):464-6.
(16) Veronese FV, Dode RS, Friderichs M, Thomé GG, da Silva DR, Schaefer PG, et al. Cocaine/levamisole-induced systemic vasculitis with retiform purpura and pauci-immune glomerulonephritis. Braz J Med Biol Res 2016; 49(5):e5244.
(17) Hikichi N, Bonda J, Lerena E. Adulterantes de cocaína: levamisol y fenacetina: presencia en huesos y otras muestras forenses. Resúmenes del IX Congreso Regional Latinoamericano de TIAFT, URUTIAFT. Cienc Forense Latinoam 2013; (Supl): 68.
(18) Chung C, Tumeh PC, Birnbaum R, Tan BH, Sharp L, McCoy E, et al. Characteristic purpura of the ears, vasculitis, and neutropenia-a potential public health epidemic associated with levamisole-adulterated cocaine. J Am Acad Dermatol 2011; 65(4):722-5.
(19) Tallarida CS, Tallarida RJ, Rawls SM. Levamisole enhances the rewarding and locomotor-activating effects of cocaine in rats. Drug Alcohol Depend 2015; 149:145-50.
(20) Tallarida CS, Egan E, Alejo GD, Raffa R, Tallarida RJ, Rawls SM. Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo. Neuropharmacology 2014; 79:590-5.
(21) Karch SB, Mari F, Bartolini V, Bertol E. Aminorex poisoning in cocaine abusers. Int J Cardiol 2012; 158(3):344-6.
(22) Buxton JA, Omura J, Kuo M, Ross C, Tzemis D, Purssell R, et al. Genetic determinants of cocaine-associated agranulocytosis. BMC Res Notes 2015; 8:240.
(23) Sirvent AE, Enríquez R, Andrada E, Sánchez M, Millán I, González C. Glomerulonefritis necrosante en el síndrome por consumo de cocaína y levamisol. Nefrología (Madr) 2016; 36(1):76-8.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.